Multifunctional polymeric implant coatings based on gelatin, hyaluronic acid derivative and chain length-controlled poly(arginine).


Journal

Materials science & engineering. C, Materials for biological applications
ISSN: 1873-0191
Titre abrégé: Mater Sci Eng C Mater Biol Appl
Pays: Netherlands
ID NLM: 101484109

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 29 03 2019
revised: 23 05 2019
accepted: 15 06 2019
entrez: 11 9 2019
pubmed: 11 9 2019
medline: 6 2 2020
Statut: ppublish

Résumé

Surface of the implantable devices is the root cause of several complications such as infections, implant loosening and chronic inflammation. There is an urgent need for multifunctional coatings that can address these shortcomings simultaneously in a manner similar to the structures of extracellular matrix. Herein, we developed a coating system composed of ECM components and a naturally derived polypeptide. The interactions between the coating components create an environment that enables incorporation of an antimicrobial/angiogenic polypeptide. The film composition is based gelatin and hyaluronic acid modified with aldehyde groups (HA-Ald) that can react with poly (arginine) (PAR) through transient interactions. Nanoplasmon measurements demonstrated a significantly higher loading of PAR in films containing HA-Ald with longer retention of PAR in the structure. The presence of PAR not only provides to the film surface antimicrobial (contact-killing) properties but also increased endothelial cell-cell contacts (PECAM) and VEGFA gene expression and secretion by human vascular endothelial cells. This multifunctional coating can be easily applied to surface of implants where it can enact on several problems simultaneously.

Identifiants

pubmed: 31499960
pii: S0928-4931(19)31187-7
doi: 10.1016/j.msec.2019.109898
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Coated Materials, Biocompatible 0
Peptides 0
Polymers 0
Vascular Endothelial Growth Factor A 0
polyarginine 25212-18-4
Gelatin 9000-70-8
Hyaluronic Acid 9004-61-9

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

109898

Informations de copyright

Copyright © 2019. Published by Elsevier B.V.

Auteurs

Helena Knopf-Marques (H)

Protip Medical, 8 Place de l'Hôpital, 67000 Strasbourg, France; INSERM UMR 1121, 11 rue Humann, 67085 Strasbourg, France.

Julien Barthes (J)

Protip Medical, 8 Place de l'Hôpital, 67000 Strasbourg, France; INSERM UMR 1121, 11 rue Humann, 67085 Strasbourg, France.

Sarah Lachaal (S)

INSERM UMR 1121, 11 rue Humann, 67085 Strasbourg, France.

Angela Mutschler (A)

INSERM UMR 1121, 11 rue Humann, 67085 Strasbourg, France; Univ. Bordeaux, CNRS, Bordeaux INP, LCPO, UMR 5629, F-33600 Pessac, France.

Céline Muller (C)

Protip Medical, 8 Place de l'Hôpital, 67000 Strasbourg, France.

Florent Dufour (F)

Protip Medical, 8 Place de l'Hôpital, 67000 Strasbourg, France.

Morgane Rabineau (M)

INSERM UMR 1121, 11 rue Humann, 67085 Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie Dentaire, Fédération de Médecine Translationnelle de Strasbourg, Fédération de Recherche Matériaux et Nanosciences Grand Est, 67000 Strasbourg, France.

Edwin-Joffrey Courtial (EJ)

3dFAB Université Lyon 1 - CNRS 5246 ICBMS, Lyon, France.

Julie Bystroňová (J)

Contipro Biotech S. R. O., Dolni Dobrouc 401, 561 02 Dolni Dobrouc, Czech Republic.

Christophe Marquette (C)

3dFAB Université Lyon 1 - CNRS 5246 ICBMS, Lyon, France.

Philippe Lavalle (P)

INSERM UMR 1121, 11 rue Humann, 67085 Strasbourg, France; Université de Strasbourg, Faculté de Chirurgie Dentaire, Fédération de Médecine Translationnelle de Strasbourg, Fédération de Recherche Matériaux et Nanosciences Grand Est, 67000 Strasbourg, France. Electronic address: philippe.lavalle@inserm.fr.

Nihal Engin Vrana (NE)

Protip Medical, 8 Place de l'Hôpital, 67000 Strasbourg, France; INSERM UMR 1121, 11 rue Humann, 67085 Strasbourg, France. Electronic address: e.vrana@protipmedical.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH